- ANGLE said first sales of the Parsortix system were reported in December 2015. Sales pipeline developing in the research use market.


- Analytical and clinical study programmes developed to progress FDA clearance for Parsortix

- Planned initial FDA clearance in metastatic breast cancer

- Three world-leading US cancer centres selected to perform clinical validation work

Clinical study programmes developed and now recruiting patients in the detection of ovarian cancer, the company's first clinical application:

- Europe: Medical University of Vienna, Charite Medical University Berlin and Vivantes Network for Health

- United States: University of Rochester Medical Center Wilmot Cancer Institute

Global market for this clinical application estimated to be £300 million per annum

- Growing body of published evidence from third party cancer centres - as at 30 April 2016

- Three publications in peer-reviewed journals and 10 posters presented at cancer conferences

- Strengthened IP position provides protection until 2034. Patents granted in Europe, Australia, Canada and China during the period, building on United States IP coverage


- Maiden revenues of £0.4 million (2015: £nil) from Parsortix

- Loss from continuing operations of £5.1 million (2015: £3.9 million) reflecting planned investment to advance and drive adoption of Parsortix

- Cash balance at 30 April 2016 of £3.8 million (30 April 2015: £8.4 million)

At 8:43am: [LON:AGL] Angle PLC share price was +3p at 70p

Story provided by